SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 5, 2011
GENESIS BIOPHARMA, INC.
(Name of small business issuer specified in its charter)
| Nevada | | 000-53127 | | 75-3254381 |
| (State or other jurisdiction | | (Commission File No.) | | (I.R.S. Employer |
| of incorporation) | | | | Identification No.) |
11500 Olympic Blvd., Suite 400
Los Angeles, CA 90064
(Address of principal executive offices)
Not Applicable.
(former name or former address, if changed since last report)
(866) 963-2220
(Registrant’s telephone number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Explanatory Note
This Amendment No. 1 amends the Current Report on Form 8-K of Genesis Biopharma, Inc. filed with the Securities and Exchange Commission on October 11, 2011 (the “Report”). The Report included the Patent License Agreement (the “License Agreement”) between the Company and the National Institutes of Health, an agency of the United States Public Health Service within the Department of Health and Human Services. Portions of the filed License Agreement were omitted based upon a request for confidential treatment filed with the Securities and Exchange Commission. The application for confidential treatment has been amended, and the enclosed License Agreement has been redacted to be consistent with the amended confidential treatment request. The information previously reported in the Report is incorporated by reference into this amendment.
Item 9.01. Financial Statements and Exhibits
| (d) | Exhibits. The following exhibit is included as part of this report. |
| | |
| 10.1 | Patent License Agreement, effective October 5, 2011, by and between Genesis Biopharma, Inc. and the National Institutes of Health.† |
† Certain portions of the Exhibit have been omitted based upon a request for confidential treatment filed by us with the Securities and Exchange Commission. The omitted portions of the Exhibit have been separately filed by us with the Securities and Exchange Commission.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
| | GENESIS BIOPHARMA, INC. | |
| | | | |
| By: | /s/ ANTHONY CATALDO | |
| | | Anthony Cataldo, Chief Executive Officer | |
| | | | |
| | | | |
